🔎 Trials Near Me

Dachaigh › Lymphoma Cealla B Mòr Sgaoilte › Minnesota

Sgrùdaidhean clionaigeach Lymphoma Cealla B Mòr Sgaoilte ann an Minnesota

Tha 16 sgrùdaidhean airson Lymphoma Cealla B Mòr Sgaoilte a’ lorg phàirtichean aig làraichean ann an Minnesota.

Bailtean ann an Minnesota

Teacsa sgrùdaidh oifigeil (Beurla)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Mayo Clinic Rochester, Rochester
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT05006716

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic Health System in Albert Lea, Albert Lea
  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06834373

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • University of Minnesota Medical Center, Minneapolis
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06500273

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

  • Essentia Health Saint Joseph's Medical Center, Brainerd
  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • agus 3 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT06649812

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

  • Mayo Clinic Health Systems-Mankato, Mankato
  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 28 Sult 2026 · NCT03418038

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • Mayo Clinic - Rochester, Rochester
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07101328

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Rochester, Rochester
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 22 Sult 2026 · NCT07226843

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

  • University of Minnesota/Masonic Cancer Center, Minneapolis
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT06536049

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Rochester
A’ fastadhÌre 1/2
Aoisean 13 gu 90 · Gach gnè · Air ùrachadh 6 Lùna 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Rochester, Rochester
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 4 Lùna 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Mayo Clinic, Rochester
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT04792489

Auto Stem Cell Transplant for Lymphoma Patients

  • Masonic Cancer Center, University of Minnesota, Minneapolis
A’ fastadhÌre 2
Suas gu aois 75 · Gach gnè · Air ùrachadh 4 Samh 2025 · NCT03125642

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Essentia Health - Deer River Clinic, Deer River
  • Essentia Health Cancer Center, Duluth
  • Essentia Health Hibbing Clinic, Hibbing
  • agus 2 a bharrachd
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Dàmh 2025 · NCT05890352

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

  • Mayo Clinic in Rochester, Rochester
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Sult 2024 · NCT06238648

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.